



Biotech Daily

SPECIAL SUMMER CATCH-UP EDITION

Sunday, January 17, 2021

The Summer Catch-Up Edition was compiled by Alice Lynch

- * **ACRUX RAISES \$7.8m, SHARE PLAN FOR \$2m more**
- * **NEXT SCIENCE: BLASTX WINS CE MARK**
- * **PHARMAUST: EPICHEM EXTENDS UP-TO \$1m DNDI CONTRACT**
- * **NYRADA NYX-PCSK9I 'REDUCES CHOLESTEROL IN MICE'**
- * **VIVAZOME, BIA SEPARATIONS WORK ON EXOSOME PURIFICATION**
- * **RAINMAKER, MARCUS LIEW REDUCE IN OSTEOPORE**
- * **PERENNIAL TAKES 8.8% IN HYDRIX**
- * **INCANNEX STARTS IHL-42X MARIJUANA SLEEP APNOEA TRIAL**
- * **ELIXINOL TERMINATES PET RELEAF AGREEMENT**
- * **CRESO: ANIBIDIOL APPROVED IN URUGUAY, \$89k PURCHASE ORDER**
- * **DIRECTOR PAUL BENHAIM, RAW WITH LIFE DILUTED TO 9% IN ELIXINOL**
- * **VOLPARA 5-YEAR QUEENSLAND BREASTSCREEN CONTRACT**
- * **STARPHARMA STARTS VIRALESE COVID-19 NASAL SPRAY STUDY**
- * **UNIVERSAL BIOSENSORS, J&J LIFESCAN ANIMAL DIABETES TEST**
- * **ALTERITY, UNIQUEST LICENCE FOR PBT2 ANTIMICROBIAL**
- * **M&G REDUCES TO 9% OF STARPHARMA**
- * **K1W1 BELOW 5% IN ADHERIUM**
- * **BOD: H&H ORDERS \$871k OF SWISSE HEMP SEED OIL FOR ITALY**
- * **DIRECTOR MICHAEL STORK DILUTED TO 5.5% IN PATRYS**
- * **STEMCELL RESPONDS TO ASX 172% PRICE QUERY**
- * **PALLA LOSES FOUNDER, CEO JARROD RITCHIE**

- * PHARMAUST ETHICS APPROVAL FOR DOG CANCER TRIAL
- * MGC WINS \$5m MALTA GRANT FOR ARTEMIC FOR COVID-19
- * CANN GROUP: 1st UK MARIJUANA OIL SHIPMENT
- * GENETIC SIGNATURES: BOSTON MEDICAL EASYSscreen DISTRIBUTOR
- * PALLA APPOINTS IAIN ROSS DIRECTOR
- * AVECHO BEGINS 'OBSERVATIONAL' CBD-TPM STUDY
- * RECCE: R327, R529 ANTI-VIRAL EFFECT IN HAMSTERS
- * TGA APPROVES ORTHOCELL CELGRO
- * RESAPP ENDS RECKITT BENCKISER COUGH DIAGNOSTIC DEAL
- * NOXOPHARM APPROVED FOR OVERSEAS R&D EXPENDITURE
- * ALTHEA APPOINTS LYPHE UK, JERSEY DISTRIBUTOR
- * TELIX: 'TLX101 LENGTHENS GLIOBLASTOMA SURVIVAL'
- * INVEX TO FILE EURO APPLICATION FOR PRESENDIN FOR IIIH
- * PHARMAUST BEGINS MANUFACTURING HUMAN-GRADE MONEPANTEL
- * REDHILL OPAGANIB COVID-19 TRIAL PASSES SAFETY REVIEW
- * SIMAVITA EXTENDS \$1.4m CONVERTIBLE NOTES
- * RESONANCE: BLACKFORD INCLUDES HEPAFAT-AI IN IMAGING DEAL
- * BLACKROCK TAKES 5% OF IMMUTEP
- * ELIXINOL 17% ASX PRICE DROP QUERY
- * PHILLIP THEMATIC BELOW 5% IN ADHERIUM
- * ANTEO APPOINTS COVID-19 RAPID TEST PART MANUFACTURER
- * M&G REDUCES TO 8% OF STARPHARMA
- * BRUCE GORDON REPLACES CELLMID CHAIR DAVID KING
- * NUHEARA \$11.5m FOR HEWLETT PACKARD DEAL; END LIND FACILITY
- * CHIESI PAYS PHARMAXIS \$9m BRONCHITOL APPROVAL MILESTONE
- * ESENSE \$812k LOAN AGREEMENTS
- * MEDIBIO: FDA WANTS MORE DATA FOR MEDSLEEP APPROVAL
- * ANALYTICA RECEIVES \$649k R&D TAX INCENTIVE

- * PHILLIP ASSET MANAGEMENT TAKES 15% OF ACRUX
- * SAMUEL TERRY BELOW 5% IN ACRUX
- * PHILLIP ASSET MANAGEMENT TAKES 10% OF CYNATA
- * BLACKROCK TAKES 6.6% OF IMMUTEP
- * MACH7 APPOINTS PHILIPPE HOUSSIAU DIRECTOR
- * UNIVERSAL BIOSENSORS, BAYER \$1.3m LAB SERVICE DEAL
- * ANTERIS PLACEMENT RAISES \$1.1m
- * US PATENT FOR IMMUTEP IMP321 COMBINATION FOR CANCER
- * EXOPHARM PLEADS SCHULTZ TO ASX 68% QUERY
- * REGAL FUNDS REDUCE, DILUTED TO 10.5% OF ELIXINOL
- * BLACKROCK TAKES 8% OF IMMUTEP
- * SIMON HARRADENCE, DDH GRAHAM, LUGARNO BELOW 5% OF ACRUX
- * LIFESPOT RIGHTS RAISE \$1.6m, \$793k SHORTFALL
- * PROBIOTEC COMPLETES \$52.5m MULTIPACK LJM ACQUISITION
- * REDHILL: TOPLINE DATA SHOWS OPAGANIB BENEFIT FOR COVID-19
- * FEDERAL GOVERNMENT: \$10m FOR COVID-19 RELATED TRIALS
- * FEDERAL \$1.5m FOR DOHERTY SARS-COV-2 VACCINE
- * BIONOMICS STARTS BNC210 DOSING STUDY
- * ANTERIS TAKES \$1.2m MITCHELL R&D TAX LOAN
- * GENETIC TECH: SIMON MORRISS CEO, DR GEORGE MUCHNICKI CMO
- * INDIRA NAIDU REPLACES IMMUTEP JOINT CO-SEC TOM BLOOMFIELD
- * NOVA TAYLOR REPLACES LIFESPOT CO-SEC JUSTYN STEDWELL
- * BLACKROCK BELOW 5% IN IMMUTEP
- * CARL CHARALAMBOUS TAKES 6% OF EXOPHARM
- * REGAL FUNDS REDUCES TO 9.5% OF ELIXINOL
- * EMYRIA TO TAKE MARIJUANA EMD-003 TO TGA
- * IMEX SIGNS 41 AQUILA DEALS WORTH \$945k ARR
- * CANN, IUVO SUPPLY DEAL, 19k UNIT FIRST ORDER

- * RHYTHM PLEADS SCHULTZ, FOOL, TIM BOREHAM TO ASX 46% QUERY
- * FIL TAKES 7% OF SOMNOMED
- * ELIZABETH MCGREGOR REPLACES EXOPHARM DIRECTOR DAVID PARKER
- * ELEANORE GOODRIDGE REDUCES TO 6.4% IN NYRADA
- * GOODBYE TASMANIAN ALKALOIDS, HELLO EXTRACTAS BIOSCIENCE
- * ANTERIS 'FUNDING PACKAGE': \$1m PLACEMENT, \$19m LOANS
- * NUHEARA PLACEMENT RAISES \$11.5m, DEBT REPAID
- * CARDIEX SHARE PLAN RAISES \$3.2m
- * CMRI, LOGICBIO EXTEND VIRAL VECTOR GENE THERAPY PROGRAM
- * IMMUTEP: PATIENT DOSING COMPLETE IN PART C OF TACTI-002 TRIAL
- * IMUGENE COMPLETES HER-VAXX PATIENT RECRUITMENT
- * KAZIA BEGINS GLIOBLASTOMA AGILE TRIAL RECRUITMENT
- * MAYNE LAUNCHES GENERIC MICROGESTIN 24 FE IN THE US
- * DR DAVID STAMLER ALTERITY CEO, GEOFFREY KEMPLER CHAIR
- * PHARMAUST, LEIDEN UNI MONEPANTEL WATER SOLUBILITY RESEARCH
- * CANN GROUP RECEIVES \$3.2m R&D TAX INCENTIVE
- * MICRO-X RECEIVES \$1.95m R&D TAX INCENTIVE
- * PAINCHEK RECEIVES \$980k R&D TAX INCENTIVE
- * VIBURNUM REDUCES TO 15.5% IN UNIVERSAL BIOSENSORS
- * RICHMOND HILL CAPITAL TAKES 7% IN UNIVERSAL BIOSENSORS
- * AUSTRALIAN ETHICAL BELOW 5% IN IMPEDIMED
- * CANNVALATE TAKES 19% IN LIFESPOT
- * AUSCANN: CANNPAL'S LAYTON MILLS REPLACES CEO NICK WOOLF
- * MESOBLAST: 'REVASCOR REDUCES CARDIAC EVENTS BY 30%'
- * IMPEDIMED COMPLETES 1,100 PATIENT 'PREVENT' LYMPHOEDEMA TRIAL
- * NEUREN: EU NNZ-2591 ORPHAN STATUS FOR 3 NEURO SYNDROMES
- * COGSTATE: \$29m H1 SALES
- * ALTHEA HITS \$1m MARIJUANA SALES IN MONTH OF DECEMBER

- * **MEDIBIO BEGINS MENTAL HEALTH DETECTION TESTING**
- * **PARADICE TAKES 8% OF IMPEDIMED**
- * **ALLAN GRAY REDUCES TO 6% OF IMPEDIMED**
- * **LOUMEA REDUCES TO 5.5% OF RHYTHM**
- * **CHAIR ADAM BLUMENTHAL, ANGLO, ATLANTIC TAKE 16% OF CRESO**
- * **PLATINUM BELOW 5% IN ANTISENSE**
- * **PERENNIAL TAKES 8% OF NUHEARA**
- * **RESAPP APPOINTS MIKE CONNELL COMMERCIAL ACTIVITIES HEAD**
- * **FEDERAL, MTP \$38m FOR DIABETES, HEART DISEASE**
- * **NUHEARA LAUNCHES HP ELITE WIRELESS EARBUDS**
- * **ACRUX: FDA APPROVES GENERIC TESTOSTERONE**
- * **CRESO: PHARMA DYNAMICS \$320k PURCHASE ORDER FOR CANNAQIX**
- * **OPTISCAN: \$350k CARL ZEISS MICROSCOPES ORDER**
- * **NOXOPHARM: SAFETY REVIEW APPROVES VEYONDA DOSE INCREASE**
- * **JIMMY THOMAS, IVY PONNIAH TAKE 6% OF LIVING CELL**
- * **MGC APPOINTS NICOLE GODRESSE HEAD OF SALES**
- * **PRO MEDICUS, INTERMOUNTAIN \$40m VISAGE 7 DEAL**
- * **CYCLOPHARM: FDA APPROVES TECHNEGAS**
- * **ORTHOCELL FDA 510(k) CLEARANCE FOR CELGRO**
- * **TOTAL BRAIN RECEIVES \$1.1m R&D TAX INCENTIVE**
- * **C2, CARDIEX CHAIR CAIRNS, CEO COOPER INCREASE, DILUTED TO 20.6%**
- * **REGAL FUNDS REDUCES TO 12% OF ALTERITY**
- * **RESPIRI BEGINS WHEEZO SALES THROUGH SUPERCHEM**
- * **AYSHA HOLLINGDALE REPLACES IQ3 CO SEC GERADO INCOLLINGO**
- * **BARD1 LOSES DIRECTOR DR IRMGARD IRMINGER-FINGER**
- * **WASAGI CORP, DAVID CANNINGTON DILUTED BELOW 5% IN NUHEARA**

Detailed summaries continue on the following pages

The following articles appear in date order

Monday December 21, 2020

ACRUX RAISES \$7.8m, SHARE PLAN FOR \$2m more

[ACRUX](#)

Acrux says it has raised \$7.8 million in a placement at 15.7 cents a share and hopes to raise a further \$2 million in a share plan at the same price.

NEXT SCIENCE: BLASTX WINS CE MARK

[NEXT SCIENCE](#)

Next Science says has Conformité Européenne (CE) mark for its Blastx antimicrobial gel for infection prevention and chronic wound healing.

PHARMAUST: EPICHEM EXTENDS UP-TO \$1m DNDI CONTRACT

[PHARMAUST](#)

Pharmaust says its subsidiary Epichem has an up-to \$1.02 million contract extension with the Drugs for Neglected Diseases Initiative, to December 31, 2021

Pharmaust said Epichem would provide its synthetic and medicinal chemistry expertise to develop new treatments for “neglected diseases”.

NYRADA NYX-PCSK9I ‘REDUCES CHOLESTEROL IN MICE’

[NYRADA](#)

Nyrada says its NYX-PCSK9I reduces total cholesterol by 57 percent in mice, with 30mg/kg and 50mg/kg doses showing a dose-related response.

VIVAZOME, BIA SEPARATIONS WORK ON EXOSOME PURIFICATION

[VIVAZOME THERAPEUTICS](#)

Vivazome says it will collaborate with BIA Separations to develop “a high-efficiency downstream purification and concentration process for exosome production”.

RAINMAKER, MARCUS LIEW REDUCE IN OSTEOPORE

[OSTEOPORE](#)

Rain Maker Management and Marcus Liew say they have reduced their substantial shareholdings in Osteopore.

In 2019, the Kuala Lumpur, Malaysia-based Rain Maker and Singapore-based Mr Liew said they had become substantial in Osteopore, alongside directors Goh Khoo Seng and Prof Teoh Swee Hin (BD :Sep 30, 2019).

Rain Maker said it had reduced its holding from 15,285,927 shares (15.10%) to 13,300,927 shares (11.34%) and Mr Liew said he had reduced from 7,142,785 shares (7.06%) to 5,932,785 shares (5.06%).

PERENNIAL TAKES 8.8% IN HYDRIX

[HYDRIX](#)

Sydney's Perennial Value Management say it has become substantial in Hydrix with 14,285,714 shares or 8.79 percent of the company.

Perennial said it bought the shares between November 6 and December 17, 2020 for \$4,035,714 or 28.25 cents a share

INCANNEX STARTS IHL-42X MARIJUANA SLEEP APNOEA TRIAL

[INCANNEX HEALTHCARE](#)

Incannex says it has recruited the first patients in its 48-patient, phase IIb safety and efficacy trial of the marijuana-based IHL-42X for obstructive sleep apnoea.

ELIXINOL TERMINATES PET RELEAF AGREEMENT

[ELIXINOL GLOBAL](#)

Elixinol says it has terminated its marijuana extract supply agreement with Altmed Pets, trading as Pet Releaf, effective from December 18, 2020.

Last year, Elixinol said that through its subsidiary Elixinol LLC, it had a \$US18 million (\$A26.6 million) 18-month marijuana manufacturing and supply agreement with Pet Releaf which would be renewed yearly for multiple years (BD: Aug 8, 2020).

CRESO: ANIBIDIOL APPROVED IN URUGUAY, \$89k PURCHASE ORDER

[CRESO PHARMA](#)

Creso says Uruguay's Ministry of Agriculture and Animal Feed has approved its Anibidiol cannabidiol hemp-based animal food supplement.

Creso said it had received its first purchase order for the region for \$89,000 worth of Anibidiol, which it expected to deliver by April 2021.

DIRECTOR PAUL BENHAIM, RAW WITH LIFE DILUTED TO 9% IN ELIXINOL

[ELIXINOL GLOBAL](#)

Elixinol director Paul Benhaim and Raw with Life Pty Ltd say their 29,523,008 shares in the company have been diluted from 12.25 percent to 9.42 percent, following Elixinol's \$8.2 million placement (BD: Nov 16, 2020).

Tuesday December 22, 2020

VOLPARA 5-YEAR QUEENSLAND BREASTSCREEN CONTRACT

[VOLPARA HEALTH](#)

Volpara says it has a five-year contract with BreastScreen Queensland to supply its Enterprize breast density screening software.

STARPHARMA STARTS VIRALEASE COVID-19 NASAL SPRAY STUDY

[STARPHARMA](#)

Starpharma says it has approval for a 40-patient, 14-day safety study of its Viralese antibacterial nasal spray for Covid-19 and other viruses.

Starpharma said it expected to complete by April, 2021.

UNIVERSAL BIOSENSORS, J&J LIFESCAN ANIMAL DIABETES TEST

[UNIVERSAL BIOSENSORS](#)

Universal Biosensors says it will develop a biosensor, test strip and meter for Johnson & Johnson's Lifescan to detect and monitor diabetes in animals.

Universal Biosensors said it would licence the diabetes strips from Lifescan, and the agreement would end when yearly sales the eventuating product drop below \$US10 million (\$A13.3 million) or when terminated by either party.

The company previously developed a Lifescan blood glucose test for humans.

ALTERITY, UNIQUEST LICENCE FOR PBT2 ANTIMICROBIAL

[ALTERITY THERAPEUTICS](#)

Alterity says it has licenced a technology from Uniquest to develop and commercial therapies to “combat antimicrobial resistance in superbugs”.

Alterity said the technology licenced from Brisbane-based Uniquest’s combined Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multi-drug resistant bacteria.

M&G REDUCES TO 9% OF STARPHARMA

[STARPHARMA](#)

London’s M&G Investment Management says it has reduced its substantial holding in Starpharma from 41,674,452 shares (10.35%) to 37,891,465 shares (9.33%).

M&G said it sold shares October 7 and December 18, 2020 with the single largest sale on October 14 of 735,777 shares for \$1,107,344 or \$1.50 a share.

K1W1 BELOW 5% IN ADHERIUM

[ADHERIUM](#)

K One W One (K1W1) says its 33,836,351 shares in Adherium have been diluted below five percent, following the issue of shares by the company.

BOD: H&H ORDERS \$871k OF SWISSE HEMP SEED OIL FOR ITALY

[BOD AUSTRALIA](#)

Bod says it has received an order from Health & Happiness Group for \$871,413 of its Swisse Wellness brand hemp seed oil products for sale in Italy.

DIRECTOR MICHAEL STORK DILUTED TO 5.5% IN PATRYS

[PATRYS](#)

Patrys director Michael Stork and Stork Holdings say their 98,773,814 shares in Patrys have been diluted from 6.91 percent to 5.46 percent, following the company’s \$4.9 million capital raising (BD: Nov 9, Dec 11, 2020).

STEMCELL RESPONDS TO ASX 172% PRICE QUERY

[STEMCELL UNITED](#)

Stemcell has responded to an ASX query regarding a 172.2 percent rise in the company’s share price between December 7 and 9, 2020.

The ASX said Stemcell’s share price rose from a low of 1.8 cents on December 7 to a high of 4.9 cents on December 9, 2020.

PALLA LOSES FOUNDER, CEO JARROD RITCHIE

[PALLA PHARMA](#)

Palla says founder and chief executive officer Jarrod Ritchie has resigned from the company, effective immediately, with chief financial officer Brendan Middleton appointed interim chief executive officer.

PHARMAUST ETHICS APPROVAL FOR DOG CANCER TRIAL

[PHARMAUST](#)

Pharmaust says it has ethics approval for a trial of monepantel for dogs with B cell lymphoma and will begin the trial by March 2021.

MGC WINS \$5m MALTA GRANT FOR ARTEMIC FOR COVID-19

[MGC PHARMACEUTICALS](#)

MGC says it has received EUR3.1 million (\$A5.0 million) Malta Enterprise grant to fund a European manufacturing facility for its anti-inflammatory Artemic for Covid-19. MGC said the construction of the facility was expected to be completed by July 2021.

CANN: 1st UK MARIJUANA OIL SHIPMENT

[CANN GROUP](#)

Cann says has shipped its first medical marijuana oil to UK distributor, Astral Health, to supply the European medical marijuana recruitment registry, Project Twenty21.

Wednesday December 23, 2020

GENETIC SIGNATURES: BOSTON MEDICAL EASYSscreen DISTRIBUTOR

[GENETIC SIGNATURES](#)

Genetic Signatures says Boston Medical Centre will distribute its Easyscreen Sars-Cov-2 detection kit, with a first order of \$US227,000 (\$A291.940 million). Genetic Signatures said Boston Medical had demand for 1,000 tests a day, but the agreement had no minimum purchase quantity.

PALLA APPOINTS IAIN ROSS DIRECTOR

[PALLA PHARMA](#)

Palla says it has appointed Iain Ross as a director, effective from December 23, 2020.

AVECHO BEGINS 'OBSERVATIONAL' CBD-TPM STUDY

[AVECHO BIOTECHNOLOGY](#)

Avecho says it has started an "observational study" of its enhanced oral cannabidiol-based tocopheryl phosphate mixture (TPM), a vitamin-E derivative. Avecho said the study was part of the Cannabis Access Clinics study, recruiting 3,000 patients to observe the effects of medical marijuana for a range of indications.

RECCE: R327, R529 ANTI-VIRAL EFFECT IN HAMSTERS

[RECCE PHARMACEUTICALS](#)

Recce says its intra-nasally administered R327 and R529 antibiotics have shown anti-viral activity against Sars-Cov-2 in a study of 40 hamsters. Recce said that both R327 and R529 outperformed the placebo, but the statistical significance had not been assessed.

TGA APPROVES ORTHOCELL CELGRO

[ORTHOCELL](#)

Orthocell says the Therapeutic Goods Administration has approved its Celgro for dental bone and tissue regeneration for sale in Australia.

RESAPP ENDS RECKITT BENCKISER COUGH DIAGNOSTIC DEAL

[RESAPP HEALTH](#)

Resapp says its memorandum of understanding with Reckitt Benckiser Group Plc for respiratory condition identification software has been terminated (BD: Jun 18, 2020). Resapp managing-director Dr Tony Keating said the parties were unable to agree "on the scope and timeframe of a joint development program".

NOXOPHARM APPROVED FOR OVERSEAS R&D EXPENDITURE

[NOXOPHARM](#)

Noxopharm says it has Federal Government approval for a 43 percent tax incentive on an unspecified amount of overseas research and development expenditure. Noxopharm said the research program would develop Veyonda, or NOX66, as an immune-oncology drug and septic shock.

ALTHEA APPOINTS LYPHE UK, JERSEY DISTRIBUTOR

[ALTHEA GROUP HOLDINGS](#)

Althea says it has appointed the London-based Lyphe Group to distribute its range of medical marijuana products in the UK and Jersey.

Althea said the agreement was for 12 months and the products would be distributed through Lyphe's pharmacies, Dispensary Green.

TELIX: 'TLX101 LENGTHENS GLIOBLASTOMA SURVIVAL'

[TELIX PHARMACEUTICALS](#)

Telix says the first eight patients in its study of TLX101 for glioblastoma have shown progression free survival of 4.33 months, compared to the average 2.5 months.

Telix said eight patients from the first cohort of its phase I/II study of TLX101 were analyzed, with two patients having died from cancer and one dead from Covid-19.

The company said the patients showed an overall survival rate of 15.97 months, the therapy was well tolerated with no limiting dosimetry to prevent higher doses.

INVEX TO FILE EURO APPLICATION FOR PRESENDIN FOR IIIH

[INVEX THERAPEUTICS](#)

Invex says it will submit a European clinical trial application for a phase III trial of its Presendin for idiopathic intracranial hypertension by July 2021.

Invex said the trial design would be based on based on European Medicines Agency guidance.

PHARMAUST BEGINS MANUFACTURING HUMAN-GRADE MONEPANTEL

[PHARMAUST](#)

Pharmaust says it has started manufacturing monepantel in India for its phase I/II human trials of monepantel for motor neuron disease and selected cancers.

Pharmaust said the monepantel tablets would be ready for use by June 2021.

REDHILL OPAGANIB COVID-19 TRIAL PASSES SAFETY REVIEW

[REDHILL BIOPHARMA](#)

Redhill says a data and safety monitoring board has recommended the continuation of its phase II/III of opaganib for Covid-19, based on safety data from 155 patients.

Redhill said top-line data from the 270-patient study was expected by April 2021.

Thursday December 24, 2020 (Christmas Eve)

SIMAVITA EXTENDS \$1.4m CONVERTIBLE NOTES

[SIMAVITA](#)

Simavita says the holders of convertible notes worth \$1.4 million have agreed to extend the maturity date by one month to January 31, 2021.

(BD: May 15, 2018; May 12, 2020).

RESONANCE: BLACKFORD INCLUDES HEPAFAT-AI IN IMAGING DEAL

[RESONANCE HEALTH](#)

Resonance says the Edinburgh, Scotland-based Blackford Analysis will provide company's artificial intelligence product Hepafat-AI for liver fat assessment through the existing imaging agreement (BD: Jul 5, 2018).

BLACKROCK TAKES 5% OF IMMUTEP

[IMMUTEP](#)

New York's Blackrock Investment Management says it has become a substantial shareholder in Immutep with 34,586,800 shares or 5.34 percent of the company. Blackrock said that between August 27 and December 22, 2020 it acquired the shares through non-cash collateral transfers.

ELIXINOL 17% ASX PRICE DROP QUERY

[ELIXINOL GLOBAL](#)

Elixinol has told the ASX that it did not consider statements made by chief executive officer Oliver Horn to be material in regard to its trading in its securities.

The ASX said the company's share price fell 16.7 percent from high of 21 cents on December 18 to a low of 17.5 on December 21, 2020 following Mr Horns address detailing that the company's performance for the three months to December 31, 2020 would be lower than the previous quarter due to Covid-19.

PHILLIP THEMATIC BELOW 5% IN ADHERIUM

[ADHERIUM](#)

The Singapore-based Phillip Thematic Fund says its 33,333,333 shares substantial holding in Adherium has been diluted below five percent following a share issue.

ANTEO APPOINTS COVID-19 RAPID TEST PART MANUFACTURER

[ANTEOTECH](#)

Anteo says it appointed an unnamed Spanish company to manufacture plastic cassettes to hold test strips for its Covid-19 Antigen rapid test.

Anteo said the development program of the test was "on track".

M&G REDUCES TO 8% OF STARPHARMA

[STARPHARMA](#)

M&G Investment Management says it has reduced its substantial holding in Starpharma from 37,023,909 shares (9.19%) to 33,225,473 shares (8.18%).

The London-based M&G said it sold shares between October 7 and December 22, 2020 with the single largest sale 735,777 shares for \$1,106,569 or \$1.50 a share.

BRUCE GORDON REPLACES CELLMID CHAIR DAVID KING

[CELLMID](#)

Cellmid says it has appointed Bruce Gordon as independent chairman to replace Dr David King, effective from January 1, 2021 (BD: Oct 21, 2020).

Monday December 28, 2020

No announcements

Tuesday December 29, 2020

NUHEARA \$11.5m FOR HEWLETT PACKARD DEAL; END LIND FACILITY

[NUHEARA](#)

Nuheara says it has raised \$11.5 million in a placement at four cents a share to fund the product manufacturing in a three-year supply deal with Hewlett Packard Inc. Nuheara said the share price was a 17 percent discount to the 15-day volume weighted average price to December 23, 2020 and Canaccord Genuity was the lead manager to the placement.

The company said it had an agreement with the Palo Alto, California-based Hewlett Packard to design, manufacture, and supply multiple HP branded products, which would carry Nuheara co-branding, beginning with wireless earbuds.

Nuheara said the wireless earbuds would be ready for commercial shipment by March 31, 2021 and the agreement had “no minimum or maximum contract value”.

CHIESI PAYS PHARMAXIS \$9m BRONCHITOL APPROVAL MILESTONE

[PHARMAXIS](#)

Pharmaxis says it has received a \$US7 million (\$A9.2 million) milestone payment from Chiesi Farmaceutici SpA for the US approval of its Bronchitol for cystic fibrosis.

Last year, Pharmaxis said the US Food and Drug Administration approved Bronchitol as “add-on maintenance therapy” for cystic fibrosis patients” (BD: Nov 2, 2020).

Today, the company said it would receive a further \$US3 million from its US licensee, the Parma, Italy-based Chiesi, on the shipment of commercial stock.

ESENSE \$812k LOAN AGREEMENTS

[ESENSE-LAB](#)

Esense says it will raise \$812,000 through loan agreements with “sophisticated and professional investors” to fund working capital, repayable by November 30, 2021.

Esense said the loan notes had an interest rate of 12 percent a year, and could be converted to Chess depository interests at 1.8 cents each, with attaching options exercisable at 1.8 cents each for 12 months, or in cash by November 30, 2021.

MEDIBIO: FDA WANTS MORE DATA FOR MEDSLEEP APPROVAL

[MEDIBIO](#)

Medibio says the US Food and Drug Administration has suggested further clinical data would be required for approval of its Medsleep sleep stage identification software device (BD: Apr 30, 2020).

ANALYTICA RECEIVES \$649k R&D TAX INCENTIVE

[ANALYTICA](#)

Analytica says it has received \$649,000 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Analytica said the rebated related to expenditure for the year to June 30, 2020.

PHILLIP ASSET MANAGEMENT TAKES 15% OF ACRUX

[ACRUX](#)

Phillip Asset Management says it has become a substantial shareholder in Acrux with 31,847,134 shares or 15.09 percent of the company.

The Melbourne-based Phillip, as trustee for Bioscience Managers Translation Fund I said it bought the shares on December 24, 2020 for 15.7 cents a share.

SAMUEL TERRY BELOW 5% IN ACRUX

[ACRUX](#)

Samuel Terry Asset Management says it has ceased its substantial shareholding in Acrux following the dilution of its 10,234,371 shares (BD: Apr 11, 2018).

PHILLIP ASSET MANAGEMENT TAKES 10% OF CYNATA

[CYNATA THERAPEUTICS](#)

Phillip Asset Management says it has become a substantial shareholder in Cynata with 14,285,715 shares or 10.33 percent of the company.

The Melbourne-based Phillip, as trustee for Bioscience Managers Translation Fund I said it bought the shares on December 23, 2020 for 70 cents a share.

BLACKROCK TAKES 6.6% OF IMMUTEP

[IMMUTEP](#)

New York's Blackrock Investment Management says it has increased its substantial holding in Immutep from 34,586,800 shares (5.34%) to 42,876,300 shares (6.61%). Blackrock said that between December 23 and 24, 2020 it acquired the shares through non-cash collateral transfers.

MACH7 APPOINTS PHILIPPE HOUSSIAU DIRECTOR

[MACH7 TECHNOLOGIES](#)

Mach7 says it has appointed the Antwerp, Belgium-based Philippe Houssiau as a non-executive director, effective from January 1, 2021.

Mach7 said Mr Houssiau was previously the chief executive officer of Agfa Healthcare and Alliance Healthcare.

Wednesday December 30, 2020

UNIVERSAL BIOSENSORS, BAYER \$1.3m LAB SERVICE DEAL

[UNIVERSAL BIOSENSORS](#)

Universal Biosensors says it has a \$C1.3 million (\$A1.33 million) agreement with the Leverkusen, Germany-based Bayer AG to supply its laboratory analysis services, through its Canadian subsidiary, Hemostasis Reverence Laboratory Inc.

ANTERIS PLACEMENT RAISES \$1.1m

[ANTERIS \(FORMERLY ADMEDUS\)](#)

Anteris says it has raised \$1.1 million in placement at \$3.37 a share to fund the development of its Duravr three-dimensional aortic valve for aortic stenosis.

Anteris the share price was a 10 percent discount to the last closing price, but the announcement would not lift its suspension, pending a "proposed capital package".

US PATENT FOR IMMUTEP IMP321 COMBINATION FOR CANCER

[IMMUTEP](#)

Immutep says the US Patent and Trademark Office has granted a patent for its IMP321 in combination with a PD-1 pathway inhibitor for cancer and infection.

Immutep said the patent, titled 'Combined Preparations for the Treatment of Cancer or Infection' would protect IMP321, or eftilagimod alpha, combined with PD-1 pathway inhibitors pembrolizumab or nivolumab until January 8, 2036.

EXOPHARM PLEADS SCHULTZ TO ASX 68% QUERY

[EXOPHARM](#)

Exopharm has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 22 cents or 67.7 percent from a closing price 32.5 cents on December 21 to an intra-day high of 54.5 cents on December 30, 2020 and noted a "significant increase" in trading volumes.

REGAL FUNDS REDUCE, DILUTED TO 10.5% OF ELIXINOL

[ELIXINOL GLOBAL](#)

Regal Funds Management says its shareholding in Elixinol has reduced and been diluted from 36,426,732 shares (15.11%) to 33,038,994 shares (10.54%).

The Sydney-based Regal Funds said the single largest sale was 400,000 shares for \$110,280 or 27.6 cents and it was diluted following a share issue.

BLACKROCK TAKES 8% OF IMMUTEP

[IMMUTEP](#)

New York's Blackrock Investment Management says it has increased its substantial holding in Immutep from 42,876,300 shares (6.61%) to 51,083,169 shares (7.88%). Blackrock said that it acquired the shares on December 28, 2020 through non-cash collateral transfers.

SIMON HARRADENCE, DDH GRAHAM, LUGARNO BELOW 5% OF ACRUX

[ACRUX](#)

Brisbane's Simon Harradence, DDH Graham and the Lugarno Fund say they have ceased their substantial shareholding in Acrux following a dilution.

In December, Acrux said it had raised \$7.8 million in a placement at 15.7 cents a share (see above).

Thursday December 31, 2020 (New Year's Eve)

LIFESPOT RIGHTS RAISE \$1.6m, \$793k SHORTFALL

[LIFESPOT HEALTH](#)

Lifespot says it has raised \$1,565,472 in a one-for-four non-renounceable, rights issue at seven cents a share, and hopes to raise a further \$793,070 in a shortfall placement.

PROBIOTEC COMPLETES \$52.5m MULTIPACK LJM ACQUISITION

[PROBIOTEC](#)

Probiotec says it has completed the acquisition of the Sydney-based contract packing company Multipack-LJM for \$52.5 million (BD: Nov 10, 2020).

REDHILL: TOPLINE DATA SHOWS OPAGANIB BENEFIT FOR COVID-19

[REDHILL BIOPHARMA](#)

Redhill says top-line data from its 40 hospitalized patients, phase II study of opaganib for Covid-19 shows it assists recovery and is safe.

Redhill said "consistent trends demonstrate greater improvement in reducing oxygen requirement by [the] end of treatment at day-14 in the opaganib-treated arm across key primary and secondary efficacy outcomes".

Sunday January 3, 2021

FEDERAL GOVERNMENT: \$10m FOR COVID-19 TRIALS

[FEDERAL GOVERNMENT](#)

The Federal Government says it will provide \$10.1 million for Covid-19 related trials, including vaccine development and other measures to slow the spread of the virus. A media release from the minister for health Greg Hunt said that six clinical trials would receive funding.

FEDERAL \$1.5m FOR DOHERTY SARS-COV-2 VACCINE

[DOHERTY INSTITUTE, FEDERAL GOVERNMENT](#)

The Doherty says the Federal Government has provided \$1.5 million for two safety trials of severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) vaccines.

The Doherty Institute said the vaccines were developed by researchers from the Doherty Institute and the Monash Institute of Pharmaceutical Sciences.

The institute said the vaccines used two different approaches focusing on the tip of the Severe acute respiratory syndrome-Coronavirus-2 (Sars-Cov-2) spike protein, known as the receptor binding domain, which mediated the virus's ability to attach and enter the cell.

Monday January 4, 2021

BIONOMICS STARTS BNC210 DOSING STUDY

[BIONOMICS](#)

Bionomics says it has begun a seven-day pharmaco-kinetic trial of BNC210 for post-traumatic stress disorder and other stress-related disorders in healthy volunteers.

Bionomics said the trial would test a solid dose tablet formulation to determine whether or not the drug could be taken without food.

In 2018, Bionomics said its 193-patient, phase II post-traumatic stress disorder trial "did not meet [the] primary endpoint", but in 2019 said it intended to change the formulation to raise BNC210 blood levels (BD: Oct 2, 2018; Jun 26, 2019).

ANTERIS TAKES \$1.2m MITCHELL R&D TAX LOAN

[ANTERIS \(FORMERLY ADMEDUS\)](#)

Anteris says it has a research and development tax incentive advance loan for \$1,220,000 at 1.15 percent interest a month from Mitchell Asset Management.

GENETIC TECH: SIMON MORRISS CEO, DR GEORGE MUCHNICKI CMO

[GENETIC TECHNOLOGIES](#)

Genetic Technologies says it has appointed Simon Morriss chief executive officer, and Dr George Muchnicki as chief medical officer, from February 1, 2021

Genetic Technologies said Dr Muchnicki has been acting chief executive officer since September 2019 and would continue as a director.

INDIRA NAIDU REPLACES IMMUTEP JOINT CO-SEC TOM BLOOMFIELD

[IMMUTEP](#)

Immutep says it has appointed Indira Naidu to replace Tom Bloomfield as joint company secretary, working with Deanne Miller.

NOVA TAYLOR REPLACES LIFESPOT CO-SEC JUSTYN STEDWELL

[LIFESPOT HEALTH](#)

Lifespot says it has appointed Nova Taylor to replace company secretary Justyn Stedwell, who will continue as an interim non-executive director.

BLACKROCK BELOW 5% IN IMMUTEP

[IMMUTEP](#)

Blackrock Investment Management says it has ceased its substantial holding in Immuteq, reducing from 51,083,169 shares (7.88%) to 4,575,169 shares (0.70%). New York's Blackrock said that between August 26 and December 31, 2020 it disposed of the shares through non-cash collateral transfers.

CARL CHARALAMBOUS TAKES 6% OF EXOPHARM

[EXOPHARM](#)

The Brisbane-based Carl Charalambous says he has become a substantial shareholder in Exopharm with 4,227,254 shares (5.05%) and on the same day said he had increased his holding to 6,292,941 shares (6.077%).

In two substantial shareholder notices, Mr Charalambous said he bought the shares between June 25 and November 13, 2020, with the single largest acquisition 1,723,788 shares for \$413,709 or 24 cents a share.

REGAL FUNDS REDUCES TO 9.5% OF ELIXINOL

[ELIXINOL GLOBAL](#)

Sydney's Regal Funds Management says it has reduced its substantial shareholding in Elixinol from 33,038,944 shares (10.54%) to 29,611,940 shares (9.45%) .

Regal Funds said that between December 21 and 29, 2020 it sold 3,427,004 shares for \$620,869 or an average of 18.1 cents a share.

Tuesday January 5, 2020

EMYRIA TO TAKE MARIJUANA EMD-003 TO TGA

[EMYRIA](#)

Emyria says it will pursue the registration of its first marijuana-based product EMD-003 with Australia's Therapeutic Goods Administration in 2021.

IMEX SIGNS 41 AQUILA DEALS WORTH \$945k ARR

[IMEX HEALTH SERVICES](#)

Imex says it has signed 41 deals for its Aquila in the Cloud, standardised radiology product between May and December 31, 2020, expected to contribute more than \$945,000 in annual recurring revenue.

CANN GROUP, IUVO SUPPLY DEAL, 19k UNIT FIRST ORDER

[CANN GROUP](#)

Cann says Iuvo Therapeutics will distribute its marijuana products in Europe and has the first order for 19,000 units of its 30ml marijuana extract.

Cann said the agreement with the Neuss, Germany Iuvo was exclusive to December 31, 2021, and would then convert to a non-exclusive agreement.

RHYTHM PLEADS SCHULTZ, FOOL, TIM BOREHAM TO ASX 46% QUERY
[RHYTHM BIOSCIENCES](#)

Rhythm has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said Rhythm's share price rose 45.1 percent from 87.5 cents on December 31, 2020 to \$1.27 on January 5, 2021 and noted an increase in the trading volume. Rhythm said the "only other explanation" could be an article in the Motley Fool and inclusion in the Stockhead's Experts 'Tim Boreham's 21 stocks that are primed to run in 2021 - Part II'.

FIL TAKES 7% OF SOMNOMED
[SOMNOMED](#)

FIL Limited says it has increased its substantial holding in Somnomed from 3,519,239 shares (6.13%) to 6,032,300 shares (7.29%).

The Hong Kong and Singapore-based FIL said it bought the shares between November 30, 2016 and December 30, 2020 at prices ranging from 80 cents to \$3.90 a share.

ELIZABETH MCGREGOR REPLACES EXOPHARM DIRECTOR DAVID PARKER
[EXOPHARM](#)

Exopharm says it has appointed Elizabeth McGregor to replace David Parker as a director effective from January 5, 2020.

Wednesday January 6, 2020

ELEANORE GOODRIDGE REDUCES TO 6.4% IN NYRADA
[NYRADA](#)

Nyrada says Eleanore Goodridge's substantial holding has reduced from 9,134,832 Chess depository instruments (CDIs) (8.34%) to 7,024,832 CDIs (6.42%).

GOODBYE TASMANIAN ALKALOIDS, HELLO EXTRACTAS BIOSCIENCE
[TASMANIAN ALKALOIDS](#)

Tasmanian Alkaloids says it has changed its name to Extractas Bioscience, effective from December 1, 2020.

ANTERIS 'FUNDING PACKAGE': \$1m PLACEMENT, \$19m LOANS
[ANTERIS \(FORMERLY ADMEDUS\)](#)

Anteris says it has a \$20 million "funding package" with Mercer Street Global Opportunity Fund LLC including a \$1 million placement at \$3.43 a share, a \$1.5 million and a \$1 million convertible note and a \$16.5 million drawdown facility.

Anteris said it has been reinstated to official quotation (see above).

Thursday January 7, 2020

NUHEARA PLACEMENT RAISES \$11.5m, DEBT REPAYED
[NUHEARA](#)

Nuheara says it has raised \$11.5 million in a placement at four cents a share and has closed out its draw-down equity facility with Lind Partners (BD: Jan 24, 2020).

CARDIEX SHARE PLAN RAISES \$3.2m

[CARDIEX](#)

Cardiex says its “over-subscribed” share plan at five cents a share has raised \$3,207,000 of a hoped-for \$1,000,000 and will not be scaled back.

CMRI, LOGICBIO EXTEND VIRAL VECTOR GENE THERAPY PROGRAM

[CHILDREN’S MEDICAL RESEARCH INSTITUTE](#)

Sydney’s Children’s Medical Research Institute says it has extended its partnership with the Lexington, Massachusetts-based Logicbio Therapeutics for two years. The Institute said that the partnership was developing “the next generation of viral vectors for gene therapy applications” and would target two new tissues.

IMMUTEP: PATIENT DOSING COMPLETE IN PART C OF TACTI-002 TRIAL

[IMMUTEP](#)

Immutep says it has completed recruitment and dosing of second-line head and neck squamous cell carcinoma patients in part C of its up-to 183 patient phase II Tacti-002 trial of IMP321, or eftilagimod alpha, with Keytruda, for cancers.

IMUGENE COMPLETES HER-VAXX PATIENT RECRUITMENT

[IMUGENE](#)

Imugene says it has completed recruitment in the 36-patient, phase II trial of its immunotherapy HER-Vaxx with chemotherapy for gastric cancer. Imugene said it reduced the number of patients in the trial from 68 to 36, and all patients have completed their baseline visit.

KAZIA BEGINS GLIOBLASTOMA AGILE TRIAL RECRUITMENT

[KAZIA THERAPEUTICS](#)

Kazia says it has begun recruitment of between 50 and 200 glioblastoma patients for the phase II/III, multi-drug glioblastoma adaptive, innovative learning environment (GBM Agile) trial of its paxalisib (BD: Dec 11, 2019; Oct 16, 2020).

MAYNE LAUNCHES GENERIC MICROGESTIN 24 FE IN THE US

[MAYNE PHARMA GROUP](#)

Mayne says it has launched its Microgestin 24 FE birth control tablets, a generic version of Loestrin 24 FE, in the US.

DR DAVID STAMLER ALTERITY CEO, GEOFFREY KEMPLER CHAIR

[ALTERITY THERAPEUTICS \(FORMERLY PRANA BIOTECHNOLOGY\)](#)

Alterity says it has appointed Dr David Stamler as chief executive officer with (Prana) founder and former executive chair Geoffrey Kempler continuing as non-executive chair, effective immediately.

Friday January 8, 2020

PHARMAUST, LEIDEN UNI MONEPANTEL WATER SOLUBILITY RESEARCH

[PHARMAUST](#)

Pharmaust says it is working with the Netherlands’ Leiden University Medical Centre to increase the water solubility of monepantel before trialling monepantel for Sars-Cov-2 (BD: Sep 24, 2020).

CANN GROUP RECEIVES \$3.2m R&D TAX INCENTIVE

[CANN GROUP](#)

Cann says it has received \$3.2 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.
Cann said the rebated related to expenditure for the year to June 30, 2020.

MICRO-X RECEIVES \$1.95m R&D TAX INCENTIVE

[MICRO-X](#)

Micro-x says it has received \$1.95 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.
Micro-x said the rebated related to expenditure for the year to June 30, 2020.

PAINCHEK RECEIVES \$980k R&D TAX INCENTIVE

[PAINCHEK](#)

Painchek says it has received \$979,621 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.
Painchek said the rebated related to expenditure for the year to June 30, 2020.

VIBURNUM REDUCES TO 15.5% IN UNIVERSAL BIOSENSORS

[UNIVERSAL BIOSENSORS](#)

Viburnum Funds says it has reduced its substantial holding in Universal Biosensors from 39,025,336 Chess depository interests (21.99%) to 27,466,227 CDIs (15.47%).
The Perth-based Viburnum said that between September 10 and 15, 2020 it bought 1,000,000 CDIs for \$336,948 or 33.7 cents each, and on January 7, 2021 it “ceased as investment manager for one fund previously managed”, reducing 12,559,109 CDIs.

RICHMOND HILL CAPITAL TAKES 7% IN UNIVERSAL BIOSENSORS

[UNIVERSAL BIOSENSORS](#)

Richmond Hill Capital says it has become substantial in Universal Biosensors with 12,559,109 Chess depository interests (CDIs) or 7.07 percent of the company.

AUSTRALIAN ETHICAL BELOW 5% IN IMPEDIMED

[IMPEDIMED](#)

The Sydney-based Australian Ethical Investments says it has ceased its substantial shareholding in Impedimed.

CANNVALATE TAKES 19% IN LIFESPOT

[LIFESPOT HEALTH](#)

Melbourne’s Cannvalate Pty Ltd says it has increased its substantial shareholding in Lifespot from 24,112,097 shares (17.89%) to 30,189,622 shares (19.21%).
Cannvalate said that between November 20, 2020 and January 5, 2021 it bought 6,077,525 shares at prices ranging between 7.0 cents and 8.8 cents a share.

AUSCANN: CANNPAL’S LAYTON MILLS REPLACES CEO NICK WOOLF

[AUSCANN GROUP HOLDINGS, CANNPAL](#)

Auscann says it has appointed Cannpal managing-director Layton Mills chief executive officer following its acquisition of Cannpal, replacing Nick Woolf (BD: Nov 16, 2020).
Auscann said Mr Woolf had resigned but would remain with the company as interim chief executive officer until June 30, 2021 to assist with the transition of leadership.

Monday January 11, 2021

MESOBLAST: 'REVASCOR REDUCES CARDIAC EVENTS BY 30%'

[MESOBLAST](#)

Mesoblast says a single dose of its Revascor "resulted in substantial and durable reductions in heart attacks, strokes, and cardiac death" in heart failure patients. Mesoblast said additional results from its 537-patient phase III trial of Revascor mesenchymal precursor cells, or rexlemestrocel-L, for patients with chronic heart failure with reduced left ventricular ejection fraction showed that rexlemestrocel-L "significantly reduced" the incident of heart attacks, strokes, and cardiac death by 30 percent compared to controls across all 537 patients (p = 0.027).

In December, the company said the trial showed a statistically significant reduction in heart attacks or strokes (p = 0.002) and death from cardiac causes (p = 0.037) but did not meet the primary endpoint of "reduction in recurrent non-fatal decompensated heart failure events" (BD: Dec 15, 2020).

Mesoblast said the rexlemestrocel-L patients had a 68 percent reduction in the rate of recurrent hospitalizations from non-fatal heart attacks or strokes compared with controls (p = 0.0002)

The company said that based on the observed reduction in mortality and morbidity the trial it intended to meet with the US Food and Drug Administration to discuss a potential approval pathway.

IMPEDIMED COMPLETES 1,100 PATIENT 'PREVENT' LYMPHOEDEMA TRIAL

[IMPEDIMED](#)

Impedimed says it has completed its more-than 1,100 patient 'Prevent' trial of its Sozo bioimpedance spectroscopy technology for lymphoedema monitoring and prevention. Impedimed said it expected to submit the trial results for journal review by March 2021.

NEUREN: EU NNZ-2591 ORPHAN STATUS FOR 3 NEURO SYNDROMES

[NEUREN PHARMACEUTICALS](#)

Neuren says the European Commission has adopted the European Medicines Agency recommendations to grant orphan designation for NNZ-2591 in Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome.

COGSTATE: \$29m H1 SALES

[COGSTATE](#)

Cogstate says it has executed \$US14.3 million (\$A18.6 million) in clinical trials sales contracts in the three months to December 31, 2020 taking the total for the six months to December 31 to \$US22.6 million, compared to \$US46.0 million for the year to June 30, 2020.

ALTHEA HITS \$1m MARIJUANA SALES IN MONTH OF DECEMBER

[ALTHEA GROUP](#)

Althea says it had record marijuana sales of \$1,190,473 in December 2020, 40 percent above November and "the first time monthly sales have exceeded \$1 million".

Althea said Australian sales were a record \$902,466 in December 2020 and UK sales were a record \$209,706.

MEDIBIO BEGINS MENTAL HEALTH DETECTION TESTING

[MEDIBIO](#)

Medibio says it has begun testing its mental health smartphone application, which aimed to detect and screen for mental health conditions by monitoring the users overnight heart rate.

PARADICE TAKES 8% OF IMPEDIMED

[IMPEDIMED](#)

Paradice Investment Management says it has increased its substantial shareholding in Impedimed from 65,941,454 shares (6.583%) to 102,899,139 shares (8.198%).

Paradice said it bought and sold shares between September 1, 2020 and January 7, 2021 with the single largest purchase of 37,271,257 shares for \$1,397,672 or 3.75 cents a share on January 7, despite the shares trading around 12 cents a share.

ALLAN GRAY REDUCES TO 6% OF IMPEDIMED

[IMPEDIMED](#)

Allan Gray Australia says it has reduced its substantial shareholding in Impedimed from 81,728,991 shares (7.60%) to 76,873,268 shares (6.12%).

The Sydney-based Allan Gray said that between November 11 and 12, 2020 it sold 4,855,723 shares for \$459,298 or 9.46 cents a share.

LOUMEA REDUCES TO 5.5% OF RHYTHM

[RHYTHM BIOSCIENCES](#)

Melbourne's Loumea Investments says it has reduced its substantial shareholding in Rhythm from 13,800,000 shares (6.85%) to 11,045,654 shares (5.48%).

Loumea said that between September 9, 2020 and January 9, 2021 it disposed of 2,754,346 shares for \$1,226,226 or 44.5 cents a share.

CHAIR ADAM BLUMENTHAL, ANGLO, ATLANTIC TAKE 16% OF CRESO

[CRESO PHARMA](#)

Adam Blumenthal, Anglo Australasia and Atlantic Capital say they have become substantial in Creso with 146,498,766 shares or 16.24 percent of the company.

The Sydney-based Mr Blumenthal said that between October 12 and December 23, 2020, 138,290,378 shares were acquired for \$4,050,000 or an average of 2.9 cents each.

PLATINUM BELOW 5% IN ANTISENSE

[ANTISENSE THERAPEUTICS](#)

The Sydney-based Platinum Investment Management says it has ceased its substantial shareholding in Antisense.

Platinum said it disposed of shares between December 17, 2020 and January 8, 2021, with the largest sale 2,000,000 shares for \$285,000 or 14.25 cents a share.

PERENNIAL TAKES 8% OF NUHEARA

[NUHEARA](#)

Sydney's Perennial Value Management says it has become a substantial shareholder in Nuheara with 137,500,000 shares or 7.98 percent of the company.

Perennial said it bought the shares on January 7, 2021 for \$6,462,500 or 4.7 cents a share.

RESAPP APPOINTS MIKE CONNELL COMMERCIAL ACTIVITIES HEAD

[RESAPP HEALTH](#)

Resapp says it has appointed Mike Connell as head of commercial activities “to lead global commercial activities”.

Tuesday January 12, 2021

FEDERAL, MTP \$38m FOR DIABETES, HEART DISEASE

[FEDERAL GOVERNMENT, MTP CONNECT](#)

MTP Connect says it will provide \$38 million to fund research for the prevention, diagnosis, management and treatment of diabetes and cardiovascular disease. MTP Connect said the funding was announced by the Federal Minister for Health and Aged Care Greg Hunt through the Targeted Translation Research Accelerator. MTP Connect said \$20 million would be allocated to the establishment of two research centres and \$18 million would be used to support translational research projects for diabetes and cardiovascular disease.

NUHEARA LAUNCHES HP ELITE WIRELESS EARBUDS

[NUHEARA](#)

Nuheara says it has launched its Hewlett Packard-branded HP Elite Wireless Earbuds and they will be available from April 2021 (BD: Aug 27, Oct 12, 2020).

ACRUX: FDA APPROVES GENERIC TESTOSTERONE

[ACRUX](#)

Acrux says the US Food and Drug Administration has approved its generic version of on Perrigo’s 30mg/1.5mL testosterone topical solution.

CRESO: PHARMA DYNAMICS \$320k PURCHASE ORDER FOR CANNAQIX

[CRESO PHARMA](#)

Creso says it has delivered a \$320,000 purchase order of its hemp oil-based food additive Cannaqix to its African distributor, the Cape Town, South Africa-based Pharma Dynamics (BD: Aug 22, 2019).

Wednesday January 13, 2020

OPTISCAN: \$350k CARL ZEISS MICROSCOPES ORDER

[OPTISCAN IMAGING](#)

Optiscan says it has orders worth about \$350,000 from Carl Zeiss Meditec AG for its Convivo microscope (BD: Oct 10, 2017; Nov 7, 2018; May 4, 2020).

NOXOPHARM: SAFETY REVIEW APPROVES VEYONDA DOSE INCREASE

[NOXOPHARM](#)

Noxopharm says an independent safety review of its trial of Veyonda, or NOX66, for Covid-19 has approved the increase of dosing to 1,800mg.

Noxopharm said the review investigated 12 patients receiving either 800mg or 1,200mg of Veyonda, and unanimously voted to increase the dosage.

JIMMY THOMAS, IVY PONNIAH TAKE 6% OF LIVING CELL

[LIVING CELL TECHNOLOGIES](#)

Jimmy Thomas and Ivy Ponniah say they have increased their substantial holding in Living Cell from 30,069,031 shares (5.26%) to 35,573,386 shares (6.23%). The Melbourne-based Mr Thomas and Ms Ponniah said that between December 2, 2020 and January 8, 2021 they bought 5,504,355 shares for \$82,565 or an average of 1.5 cents a share.

MGC APPOINTS NICOLE GODRESSE HEAD OF SALES

[MGC PHARMACEUTICALS](#)

MGC says it has appointed Nicole Godresse as head of sales to lead company sales and marketing in Australia and New Zealand.

Thursday January 14, 2021

PRO MEDICUS, INTERMOUNTAIN \$40m VISAGE 7 DEAL

[PRO MEDICUS](#)

Pro Medicus says it has a \$40 million, seven-year agreement with the Salt Lake City, Utah-based Intermountain Healthcare for its Visage 7 imaging technology. Pro Medicus said Intermountain would implement the Visage 7 technology in radiology and imaging departments at its 24 hospitals and 200 clinics, with the roll-out beginning by April 2021.

CYCLOPHARM: FDA APPROVES TECHNEGAS

[CYCLOPHARM](#)

Cyclopharm says the US Food and Drug Administration has approved its Technegas lung ventilation imaging agent for pulmonary embolism (BD: May 27, Sep 15, 2020).

ORTHOCELL FDA 510(k) CLEARANCE FOR CELGRO

[ORTHOCELL](#)

Orthocell says the US Food and Drug Administration has given 510(k) clearance to its Celgro collagen medical device for dental bone and tissue regeneration.

TOTAL BRAIN RECEIVES \$1.1m R&D TAX INCENTIVE

[TOTAL BRAIN](#)

Total Brain says it has received \$1.1 million from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program. Total Brain said the rebate related to expenditure for the year to June 30, 2020.

C2, CARDIEX CHAIR CAIRNS, CEO COOPER INCREASE, DILUTED TO 20.6%

[CARDIEX](#)

C2, Cardiex chair Niall Cairns and chief executive officer Craig Cooper say they have increased but been diluted from 158,960,194 shares (21.10%) to 177,242,010 shares (20.60%).

Sydney's C2 Ventures said that on January 12, 2021 it converting notes to acquire 17,681,818 shares for \$516,250 or 2.9 cents a share.

On January 7, 2021 Cardiex said it raised \$3,207,000 in an "over-subscribed" share plan (see above).

REGAL FUNDS REDUCES TO 12% OF ALTERITY

[ALTERITY THERAPEUTICS](#)

Sydney's Regal Funds Management says it has reduced its substantial holding in Althea from 262,791,109 shares (12.94%) to 238,853,236 shares (11.76%).

Regal Funds said that between November 26 and January 12, 2021 it sold 23,937,873 shares for \$772,888 or 3.2 cents a share.

RESPIRI BEGINS WHEEZO SALES THROUGH SUPERCHEM

[RESPIRI](#)

Respiri says the Perth-based Superchem has begun selling its Wheezo device for asthma management in its 1,000 shops across Australia.

AYSHA HOLLINGDALE REPLACES IQ3 CO SEC GERADO INCOLLINGO

[IQ3](#)

IQ3 says it has appointed Aysha Hollingdale to replace Gerado Incollingo as company secretary effective from January 12, 2021.

Friday January 15, 2020

BARD1 LOSES DIRECTOR DR IRMGARD IRMINGER-FINGER

[BARD1 LIFE SCIENCES](#)

Bard1 says director Dr Irmgard Irminger-Finger has resigned from the board but will continue to provide scientific expertise to the company.

WASAGI CORP, DAVID CANNINGTON DILUTED BELOW 5% IN NUHEARA

[NUHEARA](#)

In separate announcements, the Fairfax, California-based David Cannington and Mount Lawley Western Australian Wasagi Corp say they have been diluted below the five percent substantial level in Nuheara.

In 2017, Mr Cannington and Wasagi said their 63,142,857 share-holdings had been diluted from 11.0 percent to 7.91 percent (BD: Oct 9, 2017).